Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 aquitaine cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 4, 2013, Pages 430-435

  Lawson Ayayi, Sylvie ^a,b,c   Cazanave, Charles ^c,d   Kpozehouen, Alphonse ^a,b   Barthe, Nicole ^c   Mehsen, Nadia ^c   Hessamfar, Mojgan ^a,b,c,e   Dupon, Michel ^c,d   Dabis, François ^a,b,c   Neau, Didier ^c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d HÔPITAL PELLEGRIN   (France)

^e HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Bone mineral density; Cirrhosis; HIV; Osteoporosis; Viral hepatitis

Indexed keywords

INTERFERON; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BONE DENSITY; BONE MASS; COHORT ANALYSIS; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GROUPS BY AGE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; BONE DENSITY; CHRONIC DISEASE; COHORT STUDIES; FEMALE; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 84876395424     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182845d88     Document Type: Article

References (33)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20: 2165-2174.
2. Lawal A, Engelson E, Wang J, et al. Equivalent osteopenia in HIVinfected individuals studied before and during the era of highly active antiretroviral therapy. AIDS. 2001;15:278-280.
3. Knobel H, Guelar A, Valecillo G, et al. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001;15:807-808.
4. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003;36:S101-S105.
5. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63-F67.
6. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48:39-48.
7. Bruera D, Luna N, David DO, et al. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS. 2003;17:1917-1923.
8. Dolan SE, Huang JS, Killilea KM, et al. Reduced bone density in HIVinfected women. AIDS. 2004;18:475-483.
9. Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure of tenofovir and other antiretroviral agents. AIDS. 2012;26:825-831.
10. Hansen ABE, Gerstoft J, Kronborg G, et al. Incidence of low and highenergy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26:285-293.
11. Mundy LM, Youk AO, McComsey GA, et al. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. AIDS. 2012;26:1073-1082.
12. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367:2010-2018.
13. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22:395-402.
14. Nakchbandi IA, Van der Merwe SW. Current understanding of osteoporosis associated with liver disease. Gastroenterol Hepatol. 2009;6:660-670.
15. World Health Organization, eds. Prevention and Management of Osteoporosis. Report of a WHO Scientific Group. Geneva, Switzerland: WHO; 2003.
16. Hay JE, Guichelaar MMJ. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis. 2005;9:747-766.
17. Leslie WD, Bernstein CN, Leboff MS. American Gastroenterology Association technical review on osteoporosis in hepatic disorders. Gastroenterol. 2003;125:941-966.
18. George J, Ganesh HK, Acharya S, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol. 2009;15:3516-3522.
19. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46: 1271-1278.
20. Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005;11:1843-1847.
21. Gallego Rojo FJ, Gonzalez-Calvin JL, Muños-Torres M, et al. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998;28:695-699.
22. Collin F, Duval X, Le Moing V, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS. 2009; 23:1021-1026.
23. Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011; 52:1061-1068.
24. Lo Re V III, Guaraldi G, Leonard MB, et al. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS. 2009;23:2191-2198.
25. Loko MA, Salmon D, Carrieri P, et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis. 2010;10: 303-313.
26. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705-1713.
27. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-1075.
28. Fausto A, Bongiovanni M, Cicconi P, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38:893-897.
29. Jacobson DL, Spiegelman D, Knox TK, et al. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the Nutrition for Healthy Living Study. J Acquir Immune Defic Syndr. 2008;49:298-308.
30. Bolland MJ, Grey AB, Gamble GD, et al. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007;92:4522-4528.
31. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir- lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203: 1791-1801.
32. Mehsen N, Lawson-Ayayi S, Schaeverbeke T, et al. Cardiovascular risk and osteoporosis are associated in HIV-infected patients, ANRS CO3 Aquitaine Cohort, France [Abstract TUPE246]. Presented at: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 17-20, 2011; Roma, Italy.
33. Kerschan-Schindl K, Wendlova J, Kudlacek S, et al. Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. Exp Clin Endocrinol Diabetes. 2008;116:491-495.